AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JAN 7 - (NewsRx.com & NewsRx.net) -- Chiron Corporation (CHIR) announced that it increased production of its Fluvirin flu vaccine for the U.S. 2003-2004 flu season to 38 million doses, approximately 50% more than the previous flu season.
Through production gains from planned efficiency measures during the production cycle, the company supplied 13 million additional doses of Fluvirin to U.S. distributors over last season.
Chiron has sold all of its Fluvirin doses, utilizing its expanded network of specialty vaccine distributors to handle the increased shipments. Chiron believes there is currently a limited quantity of vaccine available in the distribution chain. Given the current high demand for flu vaccine, Chiron is also working with the U.S. Centers for Disease Control and Prevention (CDC) to assess the possibility of using extra production material to supply an additional 400,000 Fluvirin doses.
"Vaccination is one of the most effective ways to protect human health, and its role is growing as health authorities and the general public become increasingly aware of its value," said Howard Pien, Chiron president and CEO. "Globally, our flu vaccines have reached tens of millions of people this year, protecting both healthy and high-risk populations as the flu season intensifies. Continued investment in our production capacity will allow us to increase our impact on human health."
In total, Chiron produced 75 million doses of its four brands of flu vaccine for the global market, with production in ...
Source: HighBeam Research, Fluvirin influenza vaccine production increased by 50%.